Therapeutic Indications

Agalsidase beta is indicated for:

Fabry Disease

Irrespective of gender only Children (1 year - 12 years old) , Adolescents (12 years - 18 years old)

Agalsidase beta is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency).

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 1 mg/kg body weight once every 2 weeks

Fabry Disease

Irrespective of gender only Adults (18 - 65 years old)

Agalsidase beta is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency). 2

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 1 mg/kg body weight once every 2 weeks

Contraindications

Active ingredient Agalsidase beta is contraindicated in the following cases:

Chloroquine

No gender/age discrimination

Agalsidase beta should not be co-administered with chloroquine since this substance has the potential to inhibit intra-cellular α-galactosidase activity.